Multi-modality combinations of SPECT/CT and PET/CT have proven to be highly successful in the clinic and small animal SPECT/CT and PET/CT are becoming the norm in the research and drug development setting. However, the use of ionizing radiation from a high-resolution CT scanner is undesirable in any setting and particularly in small animal imaging (SAI), in laboratory experiments where it can result in radiation doses of sufficient magnitude that the experimental results can be influenced by the organism's response to radiation. The alternative use of magnetic resonance (MR) would offer a high-resolution, non-ionizing method for anatomical imaging of laboratory animals. MR brings considerably more than its 3D anatomical capability, especially regarding the imaging of laboratory animals. Dynamic MR imaging techniques can facilitate studies of perfusion, oxygenation, and diffusion amongst others. Further, MR spectroscopy can provide images that can be related to the concentration of endogenous molecules in vivo. MR imaging of injected contrast agents extends MR into the domain of molecular imaging. In combination with nuclear medicine (NM) SPECT and PET modalities in small animal imaging, MR would facilitate studies of dynamic processes such as biodistribution, pharmacokinetics, and pharmacodynamics. However, the detectors for nearly all PET and SPECT systems are still based on vacuum tube technology, namely: photomultiplier tubes (PMT's) in which the signal is generated by transporting electrons over a substantial distance within an evacuated glass tube, making them inoperable in even small magnetic fields. Thus the combination of SPECT or PET with MR has not been practical until the recent availability of semiconductor detectors such as silicon avalanche photodiodes (APD's) for PET and CdZnTe (CZT) detectors for SPECT coupled with the availability of high-density low noise ASIC electronics to read out the semiconductor detectors. The strong advantage of these technologies over PMT's is their insensitivity to magnetic fields which makes their use in co-axial multi-modality nuclear medicine/magnetic resonance instrumentation possible.
Introduction
The roots of multi-modality medical imaging can be traced back more than half a century, when the output from a nuclear rectilinear scanner was written onto a registered x-ray film (1). The physical combination of two full-scale imaging instruments into a single device is a more recent development. This "combined hardware" era of multi-modality medical imaging began in the mid-1990s with the introduction of a combined PET and CT device by Townsend (2) . The commercial success of the PET/CT instrument after the year 2000 was followed by the commercial introduction of the SPECT/CT combination that was originally conceived by Hasegawa (3). Pre-clinical multi-modality imaging of small animals was available in 2002 with SPECT/CT (4) and in 2005 with PET/CT (5). This family of instruments can be categorized as anatomical-molecular, in that the x-ray CT provides high resolution anatomical detail while the nuclear mo-Technology in Cancer Research & Treatment, Volume 5, Number 4, August 2006 dalities of PET and SPECT provide images of a broad range of molecular interactions as well as functional information such as perfusion, oxygenation, and metabolism. A classic example involves a spherical tumor shown on CT, but a necrotic core with a metabolically-active rim shown by the nuclear technique (6). Nuclear and CT, thus, complement one another, and even sequential imaging (vs. simultaneous) is sufficient as long as the examined subject maintains the same bed position for both studies in many cases.
The same period during which the first commercial multimodality devices were introduced saw the rapid growth in the field of Molecular Imaging (7) . The modalities most often associated with molecular imaging are: MRI, Nuclear, and Optical. Molecular Imaging (MI) allows the researcher or clinician to characterize the biological or disease process at the cellular or molecular level. In the next 5-10 years, the action of designer drugs and the response of the tissues will be monitored with MI techniques. It is hoped that one day cures utilizing genetic engineering, individualized stem cells, or bio-nanoparticles will be monitored non-invasively through the use of molecular imaging. The combination of nuclear with CT has yielded such profound clinical and preclinical usefulness today that dual modality PET/CT and SPECT/CT sales in both clinical and pre-clinical settings account for well over 50% of NM purchases within just a few years of the introduction of the dual modality technique. In the future, it is generally projected that combinations of MR with the nuclear or optical modalities will be synergistic more than complementary due to the options of simultaneously or sequentially obtaining anatomical, functional, and molecular information in one imaging session Magnetic Resonance Imaging (MRI) also offers a rich selection of capabilities that x-ray CT cannot match. The ability to select pulse sequences, to image function (e.g., perfusion and diffusion), and to visualize low concentrations of targeted contrast agents makes MRI both a superb anatomical modality that provides excellent soft tissue contrast as well as a functional and molecular modality. For these reasons, the effort to combine nuclear imaging modalities with MRI has become one of the most urgent areas of current nuclear imaging research. The main requirement and area of technical challenge is to replace the conventional scintillator/photomultiplier tube (PMT) detector, which cannot operate in a magnetic field, with a gammaray sensor that is magnetic field insensitive. The scintillator is itself compatible with use in a high magnetic field leading one to consider only replacing the PMT with a MRI-compatible alternative. The PMT has been the workhorse of nuclear imaging systems for more than five decades making nuclear imaging one of the only remaining fields where vacuum technology is still used, while in virtually all other fields where vacuum tubes had been used to provide low noise gain, they have been replaced by transistor-based integrated circuits.
The search for suitable devices to replace the Scintillator/PMT detector pair has been ongoing for several decades. Hammer and Christiansen, and then Cherry and colleagues have been investigating simultaneous MR-PET for more than ten years (8-10). In the case of PET, because of the unparalleled "volume-stopping" product (the achievable commercial volume (cm 3 ) × the stopping power) of materials such as BGO and LSO compared with the semiconductor candidates such as Si, GaAs, HgI 2 , and CdZn x Te (1-x) (CdTe and CZT) much of the PET work has sought to retain the scintillator and just replace the PMT. Because accurate image formation in PET relies on high-speed coincidence timing to identify the coincident gamma rays produced in the positron annihilation process, there is a need not just for high signal-to-noise ratio, but also for very fast response time. This has typically led to device designs incorporating gain so that timing decisions can be made based on just the very initial part of the signal produced by true coincidence events. One device that has shown a lot of promise to provide the needed performance is the silicon avalanche photodiode (Si-APD), however the use of the device has been hampered by difficulties in achieving reliable devices. Recently this situation has improved and PET devices based on APD's (11) are now offered commercially. In addition, several photonics component companies have begun to offer APD arrays (12). Large-area, high-density array structures lend themselves better to commercial production of higher resolution imaging systems than can be achieved by populating a systems with individual devices in a sparse readout.
In the field of SPECT the most common isotopes produce gamma rays with 5-10 times lower energy than PET allowing one to conceive of detectors where both the scintillator and the PMT are replaced with a single semiconductor device that at once sufficiently stops and converts the gamma rays into electrical signals. For example there have been many efforts over three decades to develop the semiconductor CZT for gamma ray imaging. This material has many potential advantages for SPECT imaging such as improved energy resolution and spatial resolution leading to significantly higher contrast images at lower doses. In moderate magnetic fields (1-100 G), Gamma Medica-Ideas researchers have compared CZT to position-sensitive PMT-based imagers. Measurements have shown the CZT to be insensitive to magnetic fields up to 100 G (Figure 1) whereas the PMT-based system failed at about 15 G ( Figure 2 ). This makes CZT an excellent candidate for a combined MR-SPECT.
Simultaneous imaging, however, places extraordinary demands on many scientific and engineering aspects of system design, since the nuclear imaging equipment must be located concentrically within the core of the magnet and functioning during MR acquisition as opposed to being co-axially located adjacent to the MR.
To develop a nuclear imaging device, be it SPECT or PET, that is compatible with high-field strength magnets, it makes sense to begin in the field of small animal rather than human imaging. There are two main reasons for this: i) small animals are used in medical research experiments such as drug development, normal growth and disease progression processes, and treatment responses, and this environment is inherently suited to test new instrumentation and modalities earlier than in the clinic, and ii) the dual-modality molecular imaging studies that are likely to be studied with the proposed instruments have not yet been proven to be clinically efficacious for human applications and, therefore, their usefulness is best proven in small animal studies.
Hardware Configurations
Two important questions that need to be addressed when considering the design of a combination of nuclear imaging with MRI are: (i) Given the engineering effort needed to refit the nuclear imaging equipment to function in a strong magnetic field, would a transportable patient/animal bed allow for the acquisition of registered image data taken in separate nuclear and MR rooms?; and (ii) If the combination must be in the same imaging room, can the scans be sequential (as with PET/CT), or must they be simultaneous?
Single Bed, Separate Imaging Rooms
During the past five years each of the major PET vendors has introduced PET/CT (and more recently SPECT/CT) sys-tems with the common feature that the PET and CT components are adjacent to one another on the same imaging axis. This has provided a wealth of clinical experience that has demonstrated that there is considerable variability in bone and muscle orientation, organ and connective tissue position, and digestive tract contents (including gas) that occurs in successive scans and software morphing (13) of imaging data taken on separate days or even in different bed positions currently is incapable of providing reliable clinical image fusion. An exception is in brain imaging, where the skull serves as a fixed geometrical entity that allows stable image registration across both time and position. But if the patient/ animal remains on the same bed and in the same orientation, can the bed be transported between MR and nuclear imaging rooms? If so, then there is little need for the complexity of the dual-modality combined device.
In the years following the introduction of combined PET/ CT, some products offered a SPECT scanner with a bed that could be moved to a CT imager. These products are no longer on the market at all, having been replaced completely with combined co-axial SPECT/CT systems. Although there may be no scientific impediment to the "moving bed" approach, the engineering details of the bed itself as well as the format and registration of the imaging data proved to be too costly to maintain the required flexibility for such a design to be commercially viable. Simply put, it is less costly to build a combined SPECT/CT than it is to provide a moving bed approach for even a single combination of separate SPECT and CT scanners, let alone a flexible selection of SPECT, PET, and CT manufacturers and models. With a combined device the designer can control the alignment variables that will ultimately create problems in the separate device approach. Nevertheless, due to the lack of MR-compatible nuclear imaging equipment in the clinic, the movable bed approach currently is the only option for clinical combination of these two modalities.
In the animal imaging domain, there are additional concerns that must be addressed. For example, nuclear imaging necessarily involves the injection of a radioactive agent. The injection needles, although quite small for the human, are quite large from the animal's perspective. Despite the desire to image an individual animal multiple times in longitudinal studies, current injection techniques allow only 10-12 injections over the lifetime of the animal due to scarring of the injection sites. Therefore, if the MR study involves the injection of a contrast agent, and the animal is to be imaged again at a later time, it will be beneficial to inject both MR and nuclear contrast with one needle stick.
Another concern in dual-modality animal imaging is the use of anesthesia. Since the two imaging modalities are being used to image a common biological process within the animal, it is preferable to examine the animal during the same session of anesthesia to avoid biological response differences between doses or types of anesthesia used. Further, the transportation of an anesthetized animal adds complexity to the bed design. Finally the time under anesthesia is limited and thus one would like to optimize the process flow so that a large fraction of time under anesthesia is utilized for imaging as opposed to animal transport. Also the removal of the animal from its original housing and the introduction of the animal into an imaging room are actions that can contaminate: i) the subject animal, ii) the imaging room; or iii) the other animals in the original housing. Special care must be practiced in returning the animal to its original housing.
Often the animal cannot be returned to the original housing structure to prevent contamination of the remaining population. The introduction of the animal into imaging rooms is of particular concern for this discussion. In order to reduce the potential for contamination of the experiment or the equipment, it is preferable to introduce the animal to one imaging room. These factors, in conjunction with the need to keep experimental variables to a minimum, argue in favor of a single-room combined device, and preferably on a common imaging axis. The experimental results, in turn, will be optimized and most reliable if the animal handling, the number of injections, and the use of anesthesia is held to a minimum. Additionally, there are economic concerns with regard to the throughput and the efficient use of scientist and technician time, as well as the cost savings through the minimization of the decontamination efforts.
Simultaneous Imaging
A common feature of all commercially available clinical PET/CT (and more recently SPECT/CT) systems is that the PET and CT components are in fact adjacent to one another co-axially on the same imaging axis. This is also true of the small animal dual modality PET-CT systems. Concentric SPECT-CT systems are available for small animal imaging, but the acquisition of data from both modalities simultaneously is technically challenging. Use of the same detectors for both modalities requires the detectors to have well-understood count-rate response (and dead-time corrections) and broad dynamic range. Furthermore, simultaneously providing for collimation of the SPECT data and shielding against cross-modality scatter is a major technical design hurdle (14). Simultaneous acquisition is more plausible for separate detector systems since the collimation constraints are removed, but one must take care to shield the SPECT detector from excessive and paralyzing count rates from scattered x-rays. Simultaneous PET/CT is not performed with the same detector (although no collimators are required for 3D PET) because the current PET resolution is insufficient for CT sampling. Thus, the nuclear and CT data in all currently available systems are collected sequentially and it, therefore, is not yet possible to obtain co-registered and fused dynamic functional-anatomical data.
The image formation mechanisms of MRI and CT are different, however, and in fact MRI and nuclear techniques do not have competitive or overlapping dual-functionality (15) as do SPECT and CT. With the advent of magnetically insensitive nuclear imaging detectors in order to perform simultaneous imaging with MRI and nuclear techniques, the animal need only be centrally located with the core of the magnet with RF coils in close proximity to the animal surface and the nuclear imaging equipment reside and operate in the volume between the RF coils and the gradient coils. Possible mutual "cross-talk" between the apparatuses must be avoided. That is, the presence and operation of the nuclear imaging equipment within the core of the magnet cannot create MRI artifacts. Furthermore, the intense and changing magnetic fields, along with the RF radiation cannot degrade the performance of the nuclear imager.
Simultaneous imaging is probably more important in the animal imaging domain than in clinical imaging. One reason for this is that in the case of small animals volumes are 10-1000 times smaller, while heart rate and respiratory rate for example are up to 10 times higher. This means that biological process that might develop in minutes to hours in humans can be over in seconds for a mouse, for example. Also, animal imaging techniques are being more often employed for drug development experiments involving biodistribution and pharmacokinetics. With a combined device, one could also imagine understanding the pharmacodynamics, i.e., the action of the drug through the combined images taken as a function of time. While traditionally ADME a experiments have required painstaking labeling and counting techniques on individual organs in large animal populations, a combined imaging device would provide these data using a modest animal population and sophisticated analysis of the dual image sets. New molecular imaging techniques that use "multiply-labeled" nanoparticles (16) or macromolecules (17) can benefit from simultaneous imaging. A multiply-labeled nanoparticle, for example, would be a particle about the size a Administration, Distribution, Metabolism, and Excretion. of a virus that has been engineered to: i) target receptors specific to certain cell types, e.g., cancer cells; ii) contain signal generating atoms for MR, e.g., gadolinium; and iii) contain signal generating atoms for nuclear, e.g., 18 F. For the study of the fate and action of labeled contrast agents, simultaneous nuclear/MRI imaging could provide dynamic (i.e., timedependent), high resolution and molecularly-specific information about disease process, drug interaction, and treatment efficacy. One modality can serve as the control measurement of a related process while the second modality measures the action of the targeted molecular process. Using the above techniques, simultaneous imaging offers deeper understanding to traditional animal imaging studies, such as that developmental biology, toxicology, genetic engineering, and the trafficking of stem and other cells.
Discussion
Injected contrast agents in MRI generally contain gadolinium due to its paramagnetic properties. Because of its toxicity, this element must be chelated or complexed in order to minimize its toxic effects in vivo (18). In general, magnetic resonance imaging has a lower "molar sensitivity" than the nuclear techniques, i.e., orders of magnitude higher concentrations must be present to generate a useful imaging signal. Recall that in CT animal imaging one must be aware of and avoid the effects of excess radiation dose. Similarly, in MR, the contrast agent must generate a useful imaging signal while minimizing its toxicity or pharmacological effect. This concern is addressed through research on innovative agents. For example, in activatable probes, a signal is generated only after the targeted molecular interaction has taken place (19). The signal, thus, becomes more detectable by suppressing the background. Other contrast agents are superparamagnetic iron oxide particles (SPIO). SPIOs are also referred to as monocrystalline iron oxide particles, or MIONs. These particles are non-toxic and their biochemical composition can be fine-tuned for targeted delivery and result in signal amplification.
Nuclear medicine radiotracers b fall into the two broad categories of "positron emitters" and "single-photon emitters." Generally, positron emitters used in nuclear medicine are from the lighter weight elements and they have shorter half-lives. The lighter weight allows the biologically relevant elements of carbon, nitrogen, oxygen, and fluorine to be represented by isotopes with relatively short half-lives (between 2 and 110 minutes). Short half-lives offer lower radiation doses and a more straight-forward temporal relationship between injection and imaging, but they preclude the imaging of biological uptake and washout processes that take longer than a few hours. The biological relevance of PET is that it offers the unique ability to probe biological processes with the exact organic molecules that are found in living organisms, differing only by the isotope (e.g., 11 C instead in place of the most abundant 12 C).
SPECT radiotracers, on the other hand, tend to include the heavier elements and they also have longer half-lives. MRI agents usually incorporate chelated Gd or iron oxide crystals, making them relatively large and heavy compared with the simple organic molecular agents of PET. SPECT tracers tend to be heavy, metallic elements like those used in MRI; whereas PET nuclides generally are more organically compatible with small molecules. Figure 3 graphically demonstrates this remarkably consistent demarcation between the radionuclide families of the two nuclear sub-fields. PET agents are divided into two sub-families: the biologically relevant and the heavier, longer-lived. The SPECT agents are heavier still, with even longer half-lives. The only obvious exception is the positron emitting isotope of iodine 124 I. Because of it's relatively long half-life, this isotope is often used in small animal PET imaging studies of iodine-labeled antibodies, which involve a long (~1 day) biological uptake/washout process.
Newer MRI techniques now being deployed in the research lab include the inspiration of gases containing "hyperpolarized" 3 He and 129 Xe. A laser is used to populate a particular polarization state at much higher levels than the thermal polarization of the endogenous isotope, offering the possibility of high resolution imaging of the airways and the lungs (20, 21) . Hyperpolized 13 C can be either inspired as with the above noble gases or injected (22) . Obviously 13 C may find many uses as a probe of the interactions of labeled molecules, but the challenge is to prepare the agent before the polarization has decayed.
Functional MRI (fMRI) with blood oxygen level-dependent (BOLD) imaging uses no contrast agent but instead measures relative differences in brain activation (oxygenation) levels between volumes of the brain with high spatial and temporal resolution (23). These differences can be induced in response to sensory-motor and cognitive tasks. Functional MRI, therefore, provides another unique image dataset to be combined with the molecularly-targeted imaging of nuclear medicine.
Concerning the combination of NM with MRI, the simplest technique is to use the high resolution MRI for anatomical context, as the CT in SPECT/CT and PET/CT devices is currently used. The high soft-tissue contrast of MRI better defines the tissue boundaries, leading to accurate quantitative analysis of the NM uptake data. In studies of developmental processes in laboratory animals, quantitative analysis done by NM/MRI techniques focuses results to a small sample b
Traditionally the term radiotracer (or radiopharmaceutical) has been used when referring to an injected, signal-generating agent used in nuclear medicine imaging. In the era of multi-modality devices, the term "contrast agent" often is applied to the radiotracer, especially by general (non-nuclear) users. population. Moreover, introducing the NM/MRI would save many animals that are necessary in the traditional method of ex vivo pathologic examination of tissue samples. It can be expected that multi-labeled contrast agents, i.e., ones that contain both nuclear and MR signal generation components, will follow the introduction of the NM-MRI instruments. Related MR and nuclear agents that differ only slightly can subtly probe biological processes (24, 25) . Different aspects of rapid, immediate processes following injection of the agent can be monitored with a simultaneous acquisition. For slower processes or unrelated mechanisms, there is no longer a need for simultaneous imaging and the sequential imaging approach would be sufficient. These "short-term" and "longterm" imaging options also hold for a single injection of a mixture of MR and nuclear contrast agents. The biological experiment designer has a vast array of options, not only with regard to the combination of contrast agents, but the relative timing of the injection and the acquisition.
In nuclear imaging, the toxicity of the agent usually is not the major concern due to the trace amounts of radiopharmaceuticals that are routinely used. For example, in clinical 201 Tl chloride imaging of the myocardium, the levels of the toxic chemical element thallium are thousands of times less than those needed to produce symptoms of clinical toxicity. The injection of isolated ionic species of radionuclides, therefore, is performed both in SPECT ( 201 Tl chloride) as well as PET ( 18 Ffluoride ion). Beyond single atoms, however, there is a divide between PET and SPECT. PET radiopharmaceuticals tend to be small molecules that have biochemical behavior similar to their endogenous counterparts. Often, the substitution of 18 F for a hydrogen atom is the only difference between an endogenous molecule and the radiopharmaceutical imaging probe. SPECT radiopharmaceuticals tend to be larger molecules than those used in PET imaging. Considering this property, the SPECT radiopharmaceuticals have more in common with MRI contrast agents. At first consideration, therefore, multi-labeled agents might tend to be SPECT-MR more often than PET-MR, because of the larger size of the SPECT agents and their longer half-lives. The small-molecule PET and larger molecule MR combinations may offer complementary experimental results. Furthermore, the MR nanoparticle can just as easily contain a PET radionuclide. In the application of labeled cells and the imaging of cell trafficking, the cells themselves represent the largest of labeled entities and the experimental usefulness of the nuclear signal generators will be differentiated by their half-lives.
Outlook
Small animal imaging with MRI became generally known in the late 1980s through dissemination of reports from Dr. G. A. Johnson's group at Duke University (26). Imaging of small animals reduces the volume of homogeneous magnetic field needed for imaging, and smaller bore magnets for imaging of rodents have an inner bore opening of 10-30 cm. However, to obtain the needed resolution for small animal imaging in a reasonable time, significantly higher magnetic field strengths are required. Thus, magnetic resonance imaging studies of animals typically require 4.7 T, and magnets up to 17 T have been reported (27). Active shielding of the magnet is necessary in state-of-the-art devices, and this dramatically reduces the strength of the fringe fields in the vicinity of the magnet. As the field strength increases, MR signal-to-noise increases, reducing the imaging voxel size achievable or, equivalently, reducing the acquisition time. Further, higher field strength increases the effect of of the chemical environment on the proton resonance frequency, i.e., the chemical shift, providing better contrast and allowing for MR spectroscopic imaging of specific chemical species, which is not possible at lower fields.
Clinical uses of MRI include orthopedic (musculoskeletal), head and neck, vascular/angiography, and general body anatomic imaging [abdomen, pelvis, thorax (28) ]. In the preclinical research arena, however, the applications for MRI are more varied and represent the vanguard of the technology. In brain imaging, the combination of functional techniques such as BOLD with nuclear imaging of agents that cross the blood-brain barrier can be studied with the proposed devices. Note that the PET radionuclides are sub-divided into the biologically relevant (lower left) and a mid-range family. The mid-range family is often used in small animal research studies, as is the "outlying" isotope of iodine, 124 I.
In oncology, the study of disease processes such as angiogenesis and the effects of therapeutic agents can be studied in animal populations. In cardiology, not only perfusion and wall motion, but such challenging imaging targets as vulnerable plaque within vessels, hypo-oxygenated myocardium following infarct, and innervation abnormalities can be studied with the proposed dual-modality system. Stem cells, genetic engineering using viral and other vectors, and nanoparticles are currently under study using the above-mentioned modalities separately; and monitoring the effects of these therapies involving these advanced technologies will be best done with quantitative localization of anatomical, functional, and molecular action of these targeted agents. Figure 4 demonstrates the complementary relationship between MRI and Nuclear technologies.
For 30 years the Harvard Joint Program in Nuclear Medicine has held an annual "Clinical Nuclear Medicine" refresher course for practicing nuclear medicine physcians. During the first 26 years, the title of the course remained unchanged. In 2004, the name was changed to "Clinical Nuclear Medicine (including PET)." In 2006, the course has been renamed again: "Clinical Nuclear Medicine; PET/CT, MRI, and Image Fusion." This change reflects the recognition that we are now in the era of multi-modality imaging, and that there is a strong need to take advantage of new semiconductor detector designs for NM in realizing multi-modality NM-MRI. This is further evidenced by recent engineering meetings such as the IEEE Nuclear Science Symposium/Medical Imaging conference (October, 2005, Fajardo, Puerto Rico), at which there were dozens of presentations on efforts to develop PET detectors that are compatible with strong magnetic fields. These world-wide, major developmental projects are underway both pre-clinically and clinically. There will likely be unforeseen benefits and spin-offs for the nuclear detector industry as they are re-engineered to be compatible with high-magnetic field equipment. Ultimately, the use of advanced imaging techniques such as NM-MRI to monitor and optimize therapies will simultaneously provide opti-mized healthcare along with a reduction in healthcare costs by avoiding or limiting ineffective treatments.
